Showing 6371-6380 of 7932 results for "".
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon
- AAD Honors Dr. Ginette Okoye with National Patient Care Hero Award for COVID-19 Testing Workhttps://practicaldermatology.com/news/aad-honors-dr-ginette-okoye-with-national-patient-care-hero-award-for-covid-19-testing-work/2460729/The American Academy of Dermatology (AAD) named board-certified dermatologist Ginette Okoye, MD, FAAD a Patient Care Hero for establishing a dedicated COVID-19 community testing site in a historically underserved neighborhood in northeast Washington, DC. Amid the initial surge in COVID-
- Sincerus Completes Financing With SWK To Support Demand For Customized Dermatologic Medicineshttps://practicaldermatology.com/news/sincerus-completes-financing-with-swk-to-support-demand-for-customized-dermatologic-medicines/2460727/Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, completed a major new round of growth financing with SWK Holdings Corporation, representing the largest investment into the company to date. Use of proceeds will include the build-out and expansion of a
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- NRS Launches Updated Version of "Understanding Rosacea" for Patientshttps://practicaldermatology.com/news/nrs-launches-updated-version-of-understanding-rosacea-for-patients/2460721/The National Rosacea Society has updated its most popular educational booklet. The new edition of “Understanding Rosacea” incorporates the updated standard classification and pathophysiology of rosacea, developed by a consensus committee and review panel of 28 rosacea experts worldwid
- Cetaphil Launches Sensitive Skin Awareness Weekhttps://practicaldermatology.com/news/cetaphil-launches-sensitive-skin-awareness-week/2460720/Happy Sensitive Skin Awareness Week! Sponsored by Cetaphil, the weeklong program kicks off on March 22nd and runs through March 28th. It will feature a lineup of dermatologists, influencers, and experts who wil
- AccuTec Blades: New Catalog Launches AccuThrive Brandhttps://practicaldermatology.com/news/accutec-blades-new-catalog-launches-accuthrive-brand/2460719/Introducing the newAccuThrive® medical brand, AccuTec Blades® Inc. has published its 2021 histology catalog. The 2021 AccuThrive blades portfolio highlights
- Launching from Nutrafol: New Pro-Strength Boostershttps://practicaldermatology.com/news/launching-from-nutrafol-new-pro-strength-boosters/2460713/New professional-strength boosters from Nutrafol extend the popular nutraceutical line, providing physicians the opportunity to individualize recommendations for each patient’s specific hair health needs. Hairbiotic MD is a professional-strength
- Baricitinib Performs Well in Phase 3 AA Trialhttps://practicaldermatology.com/news/baricitinib-performs-well-in-phase-3-aa-trial/2460709/Eli Lilly and Company and Incyte’s Baricitinib is the first JAK inhibitor to demonstrate hair regrowth in a Phase 3 alopecia areata (AA) trial. Patients with severe alopecia areata who took baricitinib 2-mg or 4-mg once daily showed a statistically significant improvemen
- Vyne Therapeutics to Move Forward with Topical Tofacitinib/Fingolimod Gel for ADhttps://practicaldermatology.com/news/vyne-therapeutics-to-move-forward-with-topical-tofacitinibfingolimod-gel-for-ad/2460707/Vyne Therapeutics Inc. plans to move forward on development of its fixed combination of pan-JAK inhibitor tofacitinib and sphingosine 1-phosphate receptor modulator fingolimod in a topical gel for mild-to-moderate atopic dermatitis. A phase 2a proof of concept study for FMX114 is planned to start